GlassScriptPhysician profile
Sousan Karimi
NPI 1497795140
$10,612.31
in general payments reported to CMS, 2019-2025
47 companies · $2,401 in 2025
The $2,401 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,385 · 2020: $905 · 2021: $1,202 · 2022: $1,391 · 2023: $1,391 · 2024: $1,938 · 2025: $2,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,693 · Education: $36.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,693.32 |
| Education | $36.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,731.08 | 2019-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,354.03 | 2019-2025 | Farxiga, Lokelma, Breztri |
| Glaxosmithkline, LLC. | $622.56 | 2019-2025 | Benlysta, Jesduvroq |
| Otsuka America Pharmaceutical, INC. | $590.35 | 2019-2025 | Jynarque, Voyxact |
| Novartis Pharmaceuticals Corporation | $551.67 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $535.00 | 2020-2025 | Terlivaz, Acthar |
| Calliditas Therapeutics US INC. | $515.22 | 2022-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $508.36 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Ardelyx, INC. | $463.89 | 2023-2025 | Ibsrela |
| Akebia Therapeutics INC | $317.91 | 2019-2025 | Vafseo, Auryxia |
| Lilly USA, LLC | $301.29 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Alnylam Pharmaceuticals INC. | $267.52 | 2023-2025 | Oxlumo, Amvuttra |
| Opko Pharmaceuticals, LLC | $254.27 | 2019-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $226.43 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $207.48 | 2021-2025 | Lupkynis |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sousan Karimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.